Funding in the amount of $2.0M from Japanese strategic investor, in the form of common equity PIPE with warrants. New funding provides for necessary resources to regain compliance with reporting obligations and listing standards. Share trading will move to the OTC Expert Market temporarily, with potential to uplist to OTCQB as soon as SEC filings are current, with plan to return to Nasdaq or to NYSE American. SANTA ANA, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or t ...

Core Viewpoint - NKGen Biotech is advancing its Phase 1/2a clinical trial for troculeucel, a novel NK cell therapy for moderate Alzheimer's disease, by activating two additional clinical trial sites in Canada and the U.S. to enhance patient recruitment and diversity [1][2][4]. Group 1: Clinical Trial Updates - NKGen has activated two new clinical trial sites: Ottawa Memory Clinic in Canada and AdventHealth Orlando in Florida, USA, which are now open for patient enrollment [1][2]. - The activation of these sites is crucial for initiating patient recruitment and ensuring the trial progresses as planned [1]. - The Ottawa Memory Clinic is recognized for its expertise in Alzheimer's research and will play a significant role in the trial for Canadian patients [2][3]. Group 2: Leadership and Expertise - Dr. Richard Bergeron, a prominent neuroscientist with extensive experience in neurodegenerative disease research, will lead the Ottawa Memory Clinic site [3][6]. - Dr. Bergeron has overseen over 60 clinical trials and is known for his work in both disease-modifying and symptomatic treatments for Alzheimer's disease [3][6]. - NKGen's CEO, Dr. Paul Y. Song, emphasized the importance of Dr. Bergeron's expertise in expanding patient access to troculeucel and achieving enrollment goals [4]. Group 3: Product Information - Troculeucel is an innovative, patient-specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate being developed for neurodegenerative disorders and various cancers [5]. - The World Health Organization has assigned the International Nonproprietary Name (INN) "troculeucel" to SNK01, marking a significant milestone in NKGen's development journey [5]. Group 4: Company Overview - NKGen Biotech is a clinical-stage biotechnology company headquartered in Santa Ana, California, focused on developing and commercializing NK cell therapeutics [8][9].